SUNG, Young Chul,성영철,KIM, Sae Won,김세원,KANG, Moon Cheol,강문철
申请号：
KRKR2017/010438
公开号：
WO2018/056736A1
申请日:
2017.09.22
申请国别(地区):
KR
年份:
2018
代理人:
摘要：
The present invention relates to a novel natural killer cell line and use thereof and, more particularly, to a novel natural killer cell line which is positive to CD2, CD11a, CD25, CD45, CD54, CD56, and HLA-DR； and negative to CD1a, CD3, CD4, CD8, CD14, CD16, CD20, CD23, CD34, TCRαβ, and TCRγδ, and use thereof such as a pharmaceutical composition comprising the same for treatment of cancer.La présente invention concerne une nouvelle lignée de cellules tueuses naturelles et une utilisation correspondante et, plus particulièrement, une nouvelle lignée de cellules tueuses naturelles qui est positive à CD2, CD11a, CD25, CD45, CD54, CD56 et HLA-DR ； et négative à CD1a, CD3, CD4, CD8, CD14, CD16, CD20, CD23, CD34, TCRαβ et TCRγδ et l'utilisation correspondante comme composition pharmaceutique la comprenant pour le traitement du cancer.본 발명은 신규 자연살해 세포주 및 그의 용도에 관한 것으로서, 보다 구체적으로는 CD2, CD11a, CD25, CD45, CD54, CD56 및 HLA-DR은 양성； 및 CD1a, CD3, CD4, CD8, CD14, CD16, CD20, CD23, CD34, TCRαβ 및 TCRγδ는 음성인 신규 자연살해 세포주 및 이를 포함하는 암 치료용 약학적 조성물 등 그의 용도를 제공한다.
